36,195 Shares in Inhibrx, Inc. (NASDAQ:INBX) Purchased by Yakira Capital Management Inc.

Yakira Capital Management Inc. bought a new position in shares of Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 36,195 shares of the company’s stock, valued at approximately $557,000. Yakira Capital Management Inc. owned about 0.25% of Inhibrx at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. purchased a new position in Inhibrx during the fourth quarter worth $28,000. JPMorgan Chase & Co. increased its position in Inhibrx by 47.8% during the 4th quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company’s stock worth $117,000 after purchasing an additional 2,457 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Inhibrx during the 4th quarter worth about $47,000. New York State Common Retirement Fund acquired a new position in Inhibrx in the 4th quarter valued at about $53,000. Finally, Corebridge Financial Inc. purchased a new position in Inhibrx in the 4th quarter valued at about $89,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Price Performance

Shares of Inhibrx stock opened at $13.34 on Friday. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $35.42. The business’s fifty day moving average is $13.39 and its two-hundred day moving average is $14.51.

Inhibrx (NASDAQ:INBX) last released its earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The company had revenue of $0.10 million during the quarter. As a group, equities analysts expect that Inhibrx, Inc. will post 104.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reissued a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.